Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pediatric Ease of Use ELLIPTA Items

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03315572
Recruitment Status : Completed
First Posted : October 20, 2017
Results First Posted : January 28, 2019
Last Update Posted : January 28, 2019
Sponsor:
Collaborator:
RTI Health Solutions(RTI HS)
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
A range of devices has been developed to administer inhaled therapy for asthma, including dry powder inhaler (DPI) devices. ELLIPTA is a DPI that is preloaded with a drug therapy to treat asthmatic subjects. The objective of this study is to revise ease of use items developed for adults to be appropriate for completion by pediatric subjects in future clinical trials and to evaluate the newly developed items in subjects with asthma aged 5 to 11 years and their caregivers. This is a cross-sectional, qualitative study that will involve pediatric subjects with asthma who are currently using an asthma maintenance inhaler and their caregivers. Two rounds of repetitive cognitive interviews will be conducted with 16 subjects in each interview set. Each interview will last approximately 45 minutes. Data provided by pediatric subjects and their caregivers during interview will be collected as field notes and audio recordings which will be transcribed.

Condition or disease Intervention/treatment
Asthma Other: Interviewer administered version of ease of use items Other: Self-administered version of ease of use items Other: Caregiver version of ease of use items

Layout table for study information
Study Type : Observational
Actual Enrollment : 28 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Qualitative Research to Support Ellipta Ease-of-Use Questions in Pediatric Patients With Asthma
Actual Study Start Date : October 17, 2017
Actual Primary Completion Date : December 1, 2017
Actual Study Completion Date : December 1, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Caregivers

Group/Cohort Intervention/treatment
Pediatric subject/caregiver dyads-first interview set
The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
Other: Interviewer administered version of ease of use items
The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.

Other: Self-administered version of ease of use items
The interview will be self-administered by subjects aged 8 to 11 years.

Other: Caregiver version of ease of use items
Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.

Pediatric subject/caregiver dyads-second interview set
The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
Other: Interviewer administered version of ease of use items
The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.

Other: Self-administered version of ease of use items
The interview will be self-administered by subjects aged 8 to 11 years.

Other: Caregiver version of ease of use items
Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.




Primary Outcome Measures :
  1. Number of Pediatric Participants With Problems Understanding Item Wording-Round 1 Interviews [ Time Frame: Up to 45 minutes ]
    The items for pediatric participants were developed to assess the concepts of overall ease of use of ELLIPTA and ease of evaluating remaining doses in inhaler. Pediatric participants aged 5 to 7 years were required to complete the interviewer-administered version and participants aged 8 to 11 years were administered self-completed version. Round 1 of the interviews evaluated 3 items to evaluate ease of use of inhaler (Items 1a, 1b and 1c), 3 items to assess the ease in evaluating remaining doses (Items 2a, 2b, 2c) and one item to assess if the pediatric participants could compare different types of inhalers (Item 3). The number of participants who had problems in understanding the item wordings has been presented. No statistical analyses were conducted for this qualitative study.

  2. Number of Pediatric Participants With Difficulty Providing Responses to Items-Round 1 Interviews [ Time Frame: Up to 45 minutes ]
    Round 1 of the interviews evaluated 3 items to evaluate ease of use of inhaler (Items 1a, 1b and 1c) and 3 items to assess the ease in evaluating remaining doses (Items 2a, 2b, 2c). Three response options were developed for these two concepts: Item 1a/2a-a verbal response scale with four options (Very easy, easy, hard, very hard); Item 1b/2b-the same four verbal response options accompanied by illustrations of faces for each verbal response; and Item 1c/2c-a verbal response scale with two options (Yes, No). The number of participants who had difficulty in providing item responses has been presented.

  3. Number of Pediatric Participants With Difficulty in Distinguishing Between the Item Responses-Round 1 Interviews [ Time Frame: Up to 45 minutes ]
    Round 1 of the interviews evaluated 3 items to evaluate ease of use of inhaler (Items 1a, 1b and 1c), 3 items to assess the ease in evaluating remaining doses (Items 2a, 2b, 2c) and one item to understand if the participants could compare different types of inhalers. Three response options were developed to assess ease of inhaler use and ease of evaluating remaining doses: Item 1a/2a-a verbal response scale with four options (Very easy, easy, hard, very hard); Item 1b/2b-the same four verbal response options accompanied by illustrations of faces for each verbal response; and Item 1c/2c-a verbal response scale with two options (Yes, No). Item 3 consisted of 3 response options (Yes, No, The same). The number of participants who had difficulty in distinguishing item responses has been presented.

  4. Number of Caregiver Participants Who Had Difficulty Providing Responses to Caregiver Items-Round 1 Interviews [ Time Frame: Up to 45 minutes ]
    Round 1 of the interviews for caregiver participants evaluated the concepts of ease of evaluating remaining doses (Item 1) and the likelihood of requesting inhaler from their child's physician (Item 2). A response scale with four options was developed for each item: Item 1 (Very easy, Easy, Difficult, Very difficult) and Item 2 (Very likely, Likely, Unlikely, Very unlikely). The number of caregivers who had difficulty in providing responses to caregiver items has been reported.

  5. Number of Pediatric Participants With Problems Understanding Item Wording-Round 2 Interviews [ Time Frame: Up to 45 minutes ]
    Based on the results of Round 1 interviews, the four level verbal response scale (Item 1a and Item 2a) of the pediatric versions were selected for further evaluation of ease of use and ease in evaluating remaining doses in Round 2. The second set of interviews were conducted to test if any further revision is required to optimize the items. The items for evaluation in Round 2 included: Item 1 and Item 2 for ease of ELLIPTA use and ease of evaluating remaining doses with a verbal scale of four options (Very easy, Easy, Hard, Very hard) and Item 3 for evaluation of the ability of participants to differentiate between inhalers consisting of three options (Yes, No, The same). The number of pediatric participants with problems understanding item wording has been presented.

  6. Number of Pediatric Participants With Difficulty Providing Responses to Items-Round 2 Interviews [ Time Frame: Up to 45 minutes ]
    The items for evaluation in Round 2 included: Item 1 and Item 2 for ease of ELLIPTA use and ease of evaluating remaining doses with a verbal scale of four options (Very easy, Easy, Hard, Very hard) and Item 3 for evaluation of the ability of participants to differentiate between inhalers consisting of three options (Yes, No, The same). The number of pediatric participants with difficulty in providing response to items has been presented.

  7. Number of Pediatric Participants With Difficulty in Distinguishing Between the Responses to Items-Round 2 Interviews [ Time Frame: Up to 45 minutes ]
    The items for evaluation in Round 2 included: Item 1 and Item 2 for ease of ELLIPTA use and ease of evaluating remaining doses with a verbal scale of four options (Very easy, Easy, Hard, Very hard) and Item 3 for evaluation of the ability of participants to differentiate between inhalers consisting of three options (Yes, No, The same). The number of pediatric participants who had difficulty in distinguishing between the response to items has been presented.

  8. Number of Caregiver Participants Who Had Difficulty Providing Responses to Caregiver Items-Round 2 Interviews [ Time Frame: Up to 45 minutes ]
    Based on the results of Round 1 interviews, both the items of caregiver version were retained for further evaluation in Round 2. The number of caregivers who had difficulty in providing responses to caregiver version of items has been presented below.

  9. Number of Additional Ease of Use Items Identified [ Time Frame: Up to 45 minutes ]
    Caregivers were asked if there were any concepts regarding ease of use that were missing from the pediatric or caregiver versions according to them. The number of ease of use items as identified by caregiver participants has been presented.


Secondary Outcome Measures :
  1. Number of Pediatric Participants Who Were Able to Use ELLIPTA Whistle [ Time Frame: Up to 45 minutes ]
    At the end of cognitive debriefing of the items, the interviewers demonstrated how to use the ELLIPTA whistle and then the pediatric participants were provided with a whistle and asked to produce an audible sound. The number of pediatric participants who were able to produce an audible sound using the ELLIPTA whistle has been presented.

  2. Number of Participants With Attempts Required to Produce an Audible Sound [ Time Frame: Up to 45 minutes ]
    At the end of cognitive debriefing of the items, the pediatric participants were asked to use the ELLIPTA whistle to produce an audible sound. The number of pediatric participants who required one to two attempts or more than three attempts to produce an audible sound has been presented.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
A convenience sample of pediatric subject and caregiver dyads consisting of pediatric asthmatic subjects aged 5 to 11 years currently using a maintenance inhaler and his or her caregiver will be included.
Criteria

Inclusion Criteria:

Child inclusion criteria

  • Be 5 to 11 years of age
  • Have asthma
  • Currently use a maintenance inhaler to treat their asthma
  • Be willing and able to provide assent
  • Be willing and able to participate in a 45-minute interview in English Caregiver inclusion criteria
  • Above 18+ years of age
  • Be a caregiver (parent or legal guardian) of a pediatric subject with asthma that meets the criteria above
  • Be willing and able to provide signed and dated informed consent and parental permission in English
  • Be willing and able to participate in a 45-minute interview

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03315572


Locations
Layout table for location information
United States, Michigan
GSK Investigational Site
Southfield, Michigan, United States, 48034
United States, North Carolina
GSK Investigational Site
Raleigh, North Carolina, United States, 27612
Sponsors and Collaborators
GlaxoSmithKline
RTI Health Solutions(RTI HS)
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
  Study Documents (Full-Text)

Documents provided by GlaxoSmithKline:

Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03315572     History of Changes
Other Study ID Numbers: 208129
HO-17-18594 ( Other Identifier: Track HO identifier )
First Posted: October 20, 2017    Key Record Dates
Results First Posted: January 28, 2019
Last Update Posted: January 28, 2019
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
caregiver
ELLIPTA
Asthma
Dry Powder Inhaler
pediatric

Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases